Boston Scientific - BSX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $60.10
  • Forecasted Upside: 12.12%
  • Number of Analysts: 17
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 15 Buy Ratings
  • 1 Strong Buy Ratings
▼ -0.37 (-0.69%)

This chart shows the closing price for BSX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Boston Scientific Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BSX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BSX

Analyst Price Target is $60.10
▲ +12.12% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $60.10, with a high forecast of $66.00 and a low forecast of $50.00. The average price target represents a 12.12% upside from the last price of $53.60.

This chart shows the closing price for BSX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 17 investment analysts is to buy stock in Boston Scientific. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 1 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/22/2023BarclaysBoost TargetOverweight ➝ Overweight$59.00 ➝ $60.00Low
9/21/2023Truist FinancialReiterated RatingBuy ➝ Buy$61.00Low
9/21/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$62.00 ➝ $64.00Low
9/21/2023CitigroupReiterated RatingBuy ➝ Buy$63.00Low
9/21/2023BTIG ResearchBoost TargetBuy ➝ Buy$62.00 ➝ $64.00Low
9/21/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$58.00 ➝ $61.00Low
9/21/2023UBS GroupBoost TargetBuy ➝ Buy$63.00 ➝ $66.00Low
9/21/2023Stifel NicolausBoost TargetBuy ➝ Buy$58.00 ➝ $60.00Low
9/21/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$60.00 ➝ $63.00Low
9/21/2023MizuhoBoost TargetNeutral ➝ Neutral$56.00 ➝ $60.00Low
9/20/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$61.00Low
9/19/2023Evercore ISIReiterated RatingOutperform ➝ Outperform$60.00Low
9/11/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$61.00Low
8/28/2023CitigroupReiterated RatingBuy ➝ Buy$63.00Low
8/28/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$61.00Low
8/28/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$58.00Low
8/28/2023MizuhoReiterated RatingNeutral ➝ Neutral$56.00Low
8/11/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$61.00Low
7/31/2023BarclaysBoost TargetOverweight ➝ Overweight$56.00 ➝ $59.00Low
7/28/2023Canaccord Genuity GroupBoost TargetBuy$58.00 ➝ $62.00Low
7/28/2023Raymond JamesBoost Target$60.00 ➝ $61.00Low
7/28/2023Needham & Company LLCBoost TargetBuy$57.00 ➝ $61.00Low
7/28/2023OppenheimerBoost Target$58.00 ➝ $59.00Low
7/19/2023Truist FinancialBoost Target$60.00 ➝ $61.00Low
7/18/2023Robert W. BairdInitiated CoverageOutperform$59.00Low
7/17/2023BTIG ResearchBoost Target$56.00 ➝ $57.00Low
7/12/2023Royal Bank of CanadaBoost Target$56.00 ➝ $58.00Low
7/6/2023Piper SandlerBoost Target$58.00 ➝ $62.00Low
6/30/202322nd Century GroupReiterated RatingInitiatesLow
6/30/2023CL KingInitiated CoverageBuy$64.00Low
5/30/2023Morgan StanleyInitiated CoverageOverweight$58.00Low
4/27/2023Stifel NicolausBoost Target$52.00 ➝ $58.00Low
4/27/2023Royal Bank of CanadaBoost Target$53.00 ➝ $56.00Low
4/27/2023Deutsche Bank AktiengesellschaftBoost Target$45.00 ➝ $55.00Low
4/27/2023BarclaysBoost Target$53.00 ➝ $56.00Low
4/18/2023MizuhoBoost Target$52.00 ➝ $56.00Low
4/17/2023Truist FinancialBoost TargetBuy$54.00 ➝ $59.00Low
4/17/2023BTIG ResearchBoost TargetBuy$53.00 ➝ $54.00Low
4/17/2023Raymond JamesBoost TargetStrong-Buy$56.00 ➝ $60.00Low
4/3/2023CitigroupBoost TargetBuy$54.00 ➝ $60.00Low
3/28/2023UBS GroupInitiated CoverageBuy$57.00Low
2/17/2023ArgusBoost Target$50.00 ➝ $55.00Low
2/2/2023JPMorgan Chase & Co.Boost TargetOverweight$48.00 ➝ $55.00Low
2/2/2023Needham & Company LLCBoost TargetBuy$48.00 ➝ $53.00Low
2/2/2023Raymond JamesBoost TargetStrong-Buy$54.00 ➝ $56.00Low
2/1/2023Stifel NicolausBoost Target$50.00 ➝ $52.00Low
1/6/2023Morgan StanleyBoost TargetOverweight$50.00 ➝ $56.00Low
1/4/2023BarclaysBoost Target$49.00 ➝ $53.00Low
12/22/2022MizuhoInitiated CoverageNeutral$52.00Low
12/20/2022Truist FinancialBoost TargetBuy$50.00 ➝ $54.00Low
12/20/2022CitigroupInitiated CoverageBuy$54.00Low
12/8/2022Raymond JamesBoost Target$48.00 ➝ $54.00Low
10/28/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$45.00 ➝ $48.00Low
10/17/2022BarclaysInitiated CoverageOverweight$49.00Low
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$50.00Low
10/11/2022Morgan StanleyBoost TargetOverweight$49.00 ➝ $50.00Low
9/9/2022Piper SandlerBoost TargetOverweight$47.00 ➝ $50.00Low
7/28/2022Canaccord Genuity GroupBoost Target$43.00 ➝ $45.00Low
7/28/2022BTIG ResearchBoost TargetBuy$45.00 ➝ $50.00Low
7/20/2022Truist FinancialLower TargetBuy$51.00 ➝ $45.00Low
7/15/2022Morgan StanleyLower TargetOverweight$51.00 ➝ $46.00Low
7/5/2022Wolfe ResearchInitiated CoverageOutperform$43.00N/A
6/29/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$51.00 ➝ $43.00Low
6/24/2022BTIG ResearchLower TargetBuy$52.00 ➝ $45.00Low
5/27/2022Needham & Company LLCUpgradeHold ➝ Buy$48.00Low
5/24/2022BTIG ResearchReiterated RatingBuy$52.00Low
5/17/2022CitigroupLower TargetBuy$52.00 ➝ $47.00N/A
4/13/2022Truist FinancialInitiated CoverageBuy$52.00Low
3/1/2022Bank of AmericaInitiated CoverageBuy ➝ BuyMedium
2/3/2022Morgan StanleyLower TargetOverweight$53.00 ➝ $51.00Low
2/3/2022Raymond JamesLower TargetStrong-Buy$51.00 ➝ $49.00High
2/3/2022SVB LeerinkLower TargetMarket Perform$48.00 ➝ $45.00High
12/21/2021Truist FinancialBoost TargetBuy$52.00 ➝ $53.00High
12/9/2021Royal Bank of CanadaInitiated CoverageOutperform$51.00Low
10/28/2021Raymond JamesLower TargetStrong-Buy$53.00 ➝ $51.00Medium
9/21/2021Morgan StanleyReiterated RatingBuy$53.00Medium
7/28/2021Credit Suisse GroupBoost TargetOutperform$50.00 ➝ $52.00Low
7/28/2021Raymond JamesBoost TargetStrong-Buy$50.00 ➝ $53.00Low
7/28/2021Morgan StanleyBoost TargetOverweight$51.00 ➝ $53.00Low
7/15/2021Needham & Company LLCSet TargetHold$42.74Medium
6/7/2021ArgusBoost TargetBuy$45.00 ➝ $50.00Low
5/26/2021Needham & Company LLCDowngradeBuy ➝ HoldHigh
5/24/2021BarclaysInitiated CoverageOverweight$51.00Low
4/29/2021Truist FinancialBoost Target$42.00 ➝ $50.00Low
4/29/2021Morgan StanleyBoost TargetOverweight$43.00 ➝ $51.00Low
4/29/2021Wells Fargo & CompanyBoost TargetIn-Line ➝ Overweight$42.00 ➝ $50.00Low
4/29/2021Deutsche Bank AktiengesellschaftBoost TargetHold$39.00 ➝ $45.00Low
4/15/2021Atlantic SecuritiesInitiated CoverageOverweight$52.00High
2/12/2021Needham & Company LLCBoost TargetBuy$43.00 ➝ $46.00Low
2/4/2021Raymond JamesBoost TargetStrong-Buy$39.00 ➝ $43.00Low
2/3/2021Piper SandlerBoost TargetIn-Line ➝ Overweight$46.00 ➝ $48.00High
2/1/2021Deutsche Bank AktiengesellschaftInitiated CoverageHoldLow
12/15/2020Morgan StanleyBoost TargetOverweight$40.00 ➝ $43.00Low
12/15/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyMedium
12/8/2020BTIG ResearchReiterated RatingBuyLow
11/18/2020Truist FinancialLower Target$47.00 ➝ $44.00Medium
11/18/2020Smith Barney CitigroupLower Target$46.00 ➝ $43.00High
11/18/2020Wells Fargo & CompanyLower TargetOverweight$44.00 ➝ $41.00High
11/18/2020Morgan StanleyLower TargetOverweight$41.00 ➝ $40.00High
11/17/2020Needham & Company LLCLower TargetBuy$50.00 ➝ $43.00High
10/29/2020Morgan StanleyLower TargetOverweight$48.00 ➝ $41.00High
9/17/2020Truist FinancialInitiated CoverageBuy$47.00 ➝ $47.00High
9/11/2020Wolfe ResearchInitiated CoverageMarket Perform$46.00Medium
7/30/2020Stifel NicolausBoost TargetBuy$45.00 ➝ $47.00Low
7/30/2020Jefferies Financial GroupBoost TargetBuy$43.00 ➝ $46.00Low
7/30/2020CitigroupBoost TargetBuy$44.00 ➝ $46.00Medium
7/30/2020SVB LeerinkBoost TargetMarket Perform$40.00 ➝ $43.00Medium
7/30/2020Morgan StanleyBoost TargetOverweight$45.00 ➝ $48.00Medium
7/29/2020Needham & Company LLCReiterated RatingBuy$50.00Medium
7/29/2020OppenheimerBoost TargetMarket Perform$41.00 ➝ $43.00Medium
6/24/2020Stifel NicolausReiterated RatingBuy$45.00Low
5/13/2020ArgusBoost TargetBuy$40.00 ➝ $42.00Low
4/30/2020CSFBBoost TargetOutperform$42.00 ➝ $43.00High
4/30/2020Wells Fargo & CompanyBoost TargetOverweight$40.00 ➝ $41.00Low
4/30/2020Credit Suisse GroupBoost TargetOutperform$42.00 ➝ $43.00Low
4/30/2020CitigroupBoost TargetBuy$40.00 ➝ $42.00Medium
4/30/2020UBS GroupLower TargetBuy$50.00 ➝ $45.00Medium
4/30/2020Stifel NicolausBoost TargetBuy$35.00 ➝ $45.00Medium
4/30/2020Raymond JamesBoost TargetStrong-Buy$42.00 ➝ $43.00High
4/30/2020OppenheimerReiterated RatingHold$46.00 ➝ $41.00Low
4/29/2020BTIG ResearchReiterated RatingBuy$44.00Low
4/29/2020Needham & Company LLCReiterated RatingBuy$46.00Low
4/23/2020SunTrust BanksLower TargetBuy$28.00 ➝ $25.00Low
4/22/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$40.00Low
4/9/2020Raymond JamesLower TargetStrong-Buy$49.00 ➝ $42.00High
4/2/2020Piper SandlerReiterated RatingBuyLow
4/2/2020Needham & Company LLCLower TargetBuy$53.00 ➝ $43.00Medium
4/1/2020The Goldman Sachs GroupUpgradeNeutral ➝ Conviction-Buy$46.00 ➝ $38.00High
3/27/2020CitigroupLower TargetBuy$48.00 ➝ $40.00Low
3/24/2020Stifel NicolausLower TargetBuy$47.00 ➝ $30.00High
3/23/2020StephensLower TargetOverweight$48.00 ➝ $35.00High
3/9/2020CfraUpgradeBuy ➝ Strong-Buy$50.00 ➝ $47.00Low
3/6/2020Credit Suisse GroupLower TargetOutperform$51.00 ➝ $46.00High
3/4/2020CitigroupInitiated CoverageBuy$48.00High
2/12/2020The Goldman Sachs GroupInitiated CoverageNeutral$46.00Low
2/6/2020BTIG ResearchInitiated CoverageBuy$46.00Low
1/15/2020CowenReiterated RatingBuy$52.00Medium
1/14/2020Piper SandlerReiterated RatingBuyLow
12/30/2019CowenBoost TargetOutperform$47.00 ➝ $52.00Low
12/20/2019JPMorgan Chase & Co.Boost TargetOverweight$50.00 ➝ $55.00Low
12/19/2019Needham & Company LLCDowngradeStrong-Buy ➝ Buy$53.00Low
12/17/2019Morgan StanleyBoost TargetOverweight$50.00 ➝ $51.00Medium
12/16/2019Wells Fargo & CompanyBoost TargetOverweight$48.00 ➝ $52.00Low
10/25/2019GuggenheimSet TargetBuy$53.00N/A
10/23/2019Needham & Company LLCReiterated RatingBuy$53.00Medium
10/14/2019Raymond JamesLower TargetStrong-Buy$50.00 ➝ $48.00Low
9/30/2019StephensSet TargetBuy$48.00Low
9/6/2019Stifel NicolausSet TargetBuy$47.00High
9/5/2019JPMorgan Chase & Co.Initiated CoverageOverweightMedium
9/3/2019BarclaysReiterated RatingOverweight$48.00High
8/30/2019Stifel NicolausSet TargetBuy$46.00Low
8/29/2019Morgan StanleySet TargetBuy$50.00Low
7/31/2019SVB LeerinkSet TargetBuy$50.00Low
7/25/2019Raymond JamesBoost TargetStrong-Buy$48.00 ➝ $50.00Medium
7/24/2019Needham & Company LLCSet TargetBuy$46.00Low
7/24/2019BTIG ResearchSet TargetBuy$46.00Low
7/24/2019Piper Jaffray CompaniesSet TargetBuy$50.00Low
6/27/2019Stifel NicolausBoost TargetBuy ➝ In-Line$44.00 ➝ $46.00Medium
6/27/2019Jefferies Financial GroupBoost TargetBuy ➝ Positive$44.00 ➝ $48.00Medium
6/27/2019Piper Jaffray CompaniesBoost TargetOverweight$42.00 ➝ $50.00Medium
6/18/2019Wells Fargo & CompanyBoost TargetOutperform$42.00 ➝ $45.00Medium
5/13/2019Evercore ISIUpgradeIn-Line ➝ Outperform$36.20Low
5/13/2019Needham & Company LLCReiterated RatingBuy$43.00Medium
4/25/2019BTIG ResearchReiterated RatingBuyHigh
2/13/2019ArgusBoost TargetBuy$43.00 ➝ $45.00Medium
2/8/2019SunTrust BanksReiterated RatingBuy$47.00Low
2/8/2019GuggenheimReiterated RatingBuy$48.00Low
2/6/2019Needham & Company LLCReiterated RatingBuy$43.00Low
1/8/2019Needham & Company LLCReiterated RatingBuy$43.00Medium
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$42.00Low
11/27/2018UBS GroupInitiated CoverageBuy ➝ Buy$45.00High
11/21/2018OppenheimerReiterated RatingHoldLow
11/21/2018BTIG ResearchReiterated RatingBuyLow
11/20/2018SunTrust BanksBoost TargetBuy$44.00Low
11/19/2018StephensReiterated RatingIn-Line ➝ Market Perform$40.00Medium
11/16/2018GuggenheimBoost TargetBuy$45.00Low
10/26/2018ArgusBoost TargetBuy ➝ Buy$41.00 ➝ $43.00Low
10/25/2018BTIG ResearchReiterated RatingBuy$45.00Medium
10/24/2018OppenheimerSet TargetHold$38.00Medium
10/22/2018CowenSet TargetBuy$39.00 ➝ $42.00Low
10/16/2018BTIG ResearchReiterated RatingBuy$45.00High
10/15/2018BarclaysInitiated CoverageOverweight ➝ Overweight$43.00High
10/15/2018Royal Bank of CanadaBoost TargetTop Pick$42.00High
10/2/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$38.00 ➝ $48.00Low
9/25/2018OppenheimerReiterated RatingHoldMedium
(Data available from 9/23/2018 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 16 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
  • 17 very positive mentions
  • 32 positive mentions
  • 7 negative mentions
  • 6 very negative mentions
  • 32 very positive mentions
  • 37 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 26 very positive mentions
  • 49 positive mentions
  • 10 negative mentions
  • 0 very negative mentions
  • 28 very positive mentions
  • 41 positive mentions
  • 10 negative mentions
  • 2 very negative mentions
  • 30 very positive mentions
  • 45 positive mentions
  • 9 negative mentions
  • 11 very negative mentions
  • 29 very positive mentions
  • 104 positive mentions
  • 27 negative mentions
  • 15 very negative mentions
  • 42 very positive mentions
  • 108 positive mentions
  • 14 negative mentions
  • 20 very negative mentions

Current Sentiment

  • 42 very positive mentions
  • 108 positive mentions
  • 14 negative mentions
  • 20 very negative mentions

Recent Stories by Sentiment

Boston Scientific logo
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $53.60
Low: $53.47
High: $54.11

50 Day Range

MA: $52.35
Low: $50.19
High: $54.68

52 Week Range

Now: $53.60
Low: $37.74
High: $55.38


9,439,902 shs

Average Volume

8,507,042 shs

Market Capitalization

$78.48 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Boston Scientific?

The following Wall Street analysts have issued reports on Boston Scientific in the last twelve months: 22nd Century Group, Inc., Argus, Barclays PLC, BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., CL King, Deutsche Bank Aktiengesellschaft, Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus,, TheStreet, Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for BSX.

What is the current price target for Boston Scientific?

21 Wall Street analysts have set twelve-month price targets for Boston Scientific in the last year. Their average twelve-month price target is $60.10, suggesting a possible upside of 12.1%. UBS Group AG has the highest price target set, predicting BSX will reach $66.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $50.00 for Boston Scientific in the next year.
View the latest price targets for BSX.

What is the current consensus analyst rating for Boston Scientific?

Boston Scientific currently has 1 hold rating, 15 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BSX will outperform the market and that investors should add to their positions of Boston Scientific.
View the latest ratings for BSX.

What other companies compete with Boston Scientific?

How do I contact Boston Scientific's investor relations team?

Boston Scientific's physical mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider's listed phone number is (508) 683-4000 and its investor relations email address is bsxinvestorre[email protected]. The official website for Boston Scientific is Learn More about contacing Boston Scientific investor relations.